1373766-78-9

Basic information

• Product Name: 6-(dimethylamino)hexyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate
• Synonyms: 6-(dimethylamino)hexyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate
• CAS NO: 1373766-78-9
• Molecular Weight: 514.621
• Mol File: 1373766-78-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 6-(dimethylamino)hexyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(dimethylamino)hexyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate(1373766-78-9)
• EPA Substance Registry System: 6-(dimethylamino)hexyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate(1373766-78-9)

Safety Data

• Hazardous Substances Data: 1373766-78-9(Hazardous Substances Data)

Upstream product

• 1373766-68-7 ethyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate 
• 1862-07-3 6-(N,N-dimethylamino)-1-hexanol 
• 1373766-72-3 C₂₃H₁₇NO₅ 
• 77156-85-5 Ethyl 4-chloro-7-methoxyquinoline-3-carboxylate 
• 536-90-3 m-Anisidine 
• 56881-19-7 Diethyl 2-<(3-methoxyphenylamino)methylene>malonate 
• 1226760-36-6 ethyl 2-bromo-4-chloro-7-methoxyquinoline-3-carboxylate 

Relevant articles and documents

Lead optimization of 3-carboxyl-4(1 H)-quinolones to deliver orally bioavailable antimalarials

Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.